Viracta Therapeutics Inc

NASDAQ:VIRX   3:59:51 PM EDT
2.39
-0.24 (-9.12%)
Products

Viracta Therapeutics Announces Orphan Drug Designation Granted By FDA For Its All-Oral Combination Of Nanatinostat And Valganciclovir (Nana-Val) For The Treatment Of Epstein Barr Virus-Positive

Published: 11/29/2021 13:28 GMT
Viracta Therapeutics Inc (VIRX) - Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for Its All-oral Combination of Nanatinostat and Valganciclovir (nana-val) for the Treatment of Epstein Barr Virus-positive Diffuse Large B-cell Lymphoma.
Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for Its All-oral Combination of Nanatinostat and Valganciclovir (nana-val) for the Treatment of Epstein Barr Virus-positive Diffuse Large B-cell Lymphoma.